Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 140 of the 141 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia. PARTICIPANTS: The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies have reported that 44-62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment (225,226).”
From Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline (2016) · cites this paper as [226]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Persistently elevated prolactin levels can indicate the presence of pituitary tumors, such as prolactinomas”
From Evaluation and Management of Testosterone Deficiency: AUA Guideline (2018) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Fernandez, A., Karavitaki, N., & Wass, J. A. H. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03667.x · Cited by 1,115
Self-citationHigh Prevalence of Pituitary Adenomas: A Cross-Sectional Study in the Province of Liège, Belgium
Daly, A. F., Rixhon, M., Adam, C., Dempegioti, A., Tichomirowa, M. A., & Beckers, A. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1668 · Cited by 1,025
Bhasin, S., Cunningham, G. R., Hayes, F. J., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., & Montori, V. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2847 · Cited by 965
Self-citationValvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Zanettini, R., Antonini, A., Gatto, G., Gentile, R., Tesei, S., & Pezzoli, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa054830 · Cited by 884
Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas
Casanueva, F. F., Molitch, M. E., Schlechte, J. A., Abs, R., Bonert, V., Bronstein, M. D., Brue, T., Cappabianca, P., Colao, A., Fahlbusch, R., et al. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02562.x · Cited by 829
Self-citationAdvances in the Treatment of Prolactinomas
Gillam, M. P., Molitch, M. E., Lombardi, G., & Colao, A. (2006) · Endocrine Reviews · doi:10.1210/er.2005-9998 · Cited by 824
A Radioimmunoassay for Human Prolactin
Hwang, P., Guyda, H., & Friesen, H. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.8.1902 · Cited by 752
Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Schade, R., Andersohn, F., Suissa, S., Haverkamp, W., & Garbe, E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062222 · Cited by 718
A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea
Webster, J., Piscitelli, G., Polli, A., Ferrari, C. I., Ismail, I., & Scanlon, M. F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311403 · Cited by 699
When are randomised trials unnecessary? Picking signal from noise
Glasziou, P., Chalmers, I., Rawlins, M., & McCulloch, P. (2007) · BMJ · doi:10.1136/bmj.39070.527986.68 · Cited by 589
Galactorrhea: A Study of 235 Cases, Including 48 with Pituitary Tumors
Kleinberg, D. L., Noel, G. L., & Frantz, A. G. (1977) · New England Journal of Medicine · doi:10.1056/nejm197703172961103 · Cited by 560
Self-citationMechanisms for pituitary tumorigenesis: the plastic pituitary
Melmed, S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320401 · Cited by 456
Self-citationCabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients
Verhelst, J., Abs, R., Maiter, D., van den Bruel, A., Vandeweghe, M., Velkeniers, B., Mockel, J., Lamberigts, G., Petrossians, P., Coremans, P., et al. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5810 · Cited by 449
MOLITCH, M. E., ELTON, R. L., BLACKWELL, R. E., CALDWELL, B., CHANG, R. J., JAFFE, R., JOPLIN, G., ROBBINS, R. J., TYSON, J., & THORNER, M. O. (1985) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-60-4-698 · Cited by 435
Kinon, B. J., Gilmore, J. A., Liu, H., & Halbreich, U. M. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00127-0 · Cited by 350
Withdrawal of Long-Term Cabergoline Therapy for Tumoral and Nontumoral Hyperprolactinemia
Colao, A., Di Sarno, A., Cappabianca, P., Di Somma, C., Pivonello, R., & Lombardi, G. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022657 · Cited by 336
Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging
GONZALEZ, J., ELIZONDO, G., SALDIVAR, D., NANEZ, H., TODD, L., & VILLARREAL, J. (1988) · The American Journal of Medicine · doi:10.1016/0002-9343(88)90542-6 · Cited by 335
Diagnosis and Management of Pituitary Carcinomas
Kaltsas, G. A., Nomikos, P., Kontogeorgos, G., Buchfelder, M., & Grossman, A. B. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2231 · Cited by 325
Swiglo, B. A., Murad, M. H., Schünemann, H. J., Kunz, R., Vigersky, R. A., Guyatt, G. H., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-1907 · Cited by 302 · cited 6×
“Practice Guidelines for Hyperprolactinemia J Clin Endocrinol Metab, February 2011, 96(2):273–288”
BackgroundInfluentialSelf-citationSerri, O., Rasio, E., Beauregard, H., Hardy, J., & Somma, M. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308043090505 · Cited by 301
The Pituitary Gland in Pregnancy: A Clinicopathologic and Immunohistochemical Study of 69 Cases
SCHEITHAUER, B. W., SANO, T., KOVACS, K. T., YOUNG, W. F., RYAN, N., & RANDALL, R. V. (1990) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60946-x · Cited by 286
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
Colao, A. (1997) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.82.3.876 · Cited by 276
The Natural History of Untreated Hyperprolactinemia: A Prospective Analysis*
SCHLECHTE, J., DOLAN, K., SHERMAN, B., CHAPLER, F., & LUCIANO, A. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-412 · Cited by 271
Self-citationResistance to Bromocriptine in Prolactinomas
PELLEGRINI, I., RASOLONJANAHARY, R., GUNZ, G., BERTRAND, P., DELIVET, S., JEDYNAK, C. P., KORDON, C., PEILLON, F., JAQUET, P., & ENJALBERT, A. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-500 · Cited by 267
Schlechte, J. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp025334 · Cited by 258
Self-citationHyperprolactinemia and Prolactinomas
Mancini, T., Casanueva, F. F., & Giustina, A. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.013 · Cited by 256
Self-citationColao, A., Vitale, G., Cappabianca, P., Briganti, F., Ciccarelli, A., De Rosa, M., Zarrilli, S., & Lombardi, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030979 · Cited by 256
Medication-Induced Hyperprolactinemia
Molitch, M. E. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.8.1050 · Cited by 250
Di Sarno, A., Landi, M. L., Cappabianca, P., Di Salle, F., Rossi, F. W., Pivonello, R., Di Somma, C., Faggiano, A., Lombardi, G., & Colao, A. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.11.8054 · Cited by 247
Klibanski, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmcp0912025 · Cited by 236
Dekkers, O. M., Lagro, J., Burman, P., Jørgensen, J. O., Romijn, J. A., & Pereira, A. M. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1238 · Cited by 230
Karavitaki, N., Thanabalasingham, G., Shore, H. C. A., Trifanescu, R., Ansorge, O., Meston, N., Turner, H. E., & Wass, J. A. H. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02627.x · Cited by 230
Self-citationColao, A., Di Sarno, A., Landi, M. L., Scavuzzo, F., Cappabianca, P., Pivonello, R., Volpe, R., Di Salle, F., Cirillo, S., Annunziato, L., et al. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.6.6657 · Cited by 227
Treatment of Acromegaly with Dopamine Agonists
Jaffe, C. A., & Barkan, A. L. (1992) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30210-x · Cited by 220
Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data
Buurman, H., & Saeger, W. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02107 · Cited by 214
Pattern of increase in circulating prolactin levels during human gestation
Rigg, L. A., Lein, A., & Yen, S. S. C. (1977) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(77)90594-4 · Cited by 207
SIEVERTSEN, G. D., LIM, V. S., NAKAWATASE, C., & FROHMAN, L. A. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-50-5-846 · Cited by 207
Increase in Bone Mass after Treatment of Hyperprolactinemic Amenorrhea
Klibanski, A., & Greenspan, S. L. (1986) · New England Journal of Medicine · doi:10.1056/nejm198608283150903 · Cited by 205
The Effects of Antipsychotic-Induced Hyperprolactinaemia on the Hypothalamic-Pituitary-Gonadal Axis
Smith, S., Wheeler, M. J., Murray, R., & O’Keane, V. (2002) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200204000-00002 · Cited by 202
Volavka, J., Czobor, P., Cooper, T. B., Sheitman, B., Lindenmayer, J.-P., Citrome, L., McEvoy, J. P., & Lieberman, J. A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0109 · Cited by 201
Toils, G., Hickey, J., & Guyda, H. (1975) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-41-4-797 · Cited by 200
What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?
Knegtering, H., van der Moolen, A. E. G. M., Castelein, S., Kluiter, H., & van den Bosch, R. J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00130-0 · Cited by 196
Smith, T. P., Suliman, A. M., Fahie-Wilson, M. N., & McKenna, T. J. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-011943 · Cited by 195
Delgrange, E., Daems, T., Verhelst, J., Abs, R., & Maiter, D. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0012 · Cited by 194
Prospective Study of High-Dose Cabergoline Treatment of Prolactinomas in 150 Patients
Ono, M., Miki, N., Kawamata, T., Makino, R., Amano, K., Seki, T., Kubo, O., Hori, T., & Takano, K. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2758 · Cited by 191
Webster, J. (1996) · Drug Safety · doi:10.2165/00002018-199614040-00003 · Cited by 186
Medical therapy for clinically non-functioning pituitary adenomas
Colao, A., Di Somma, C., Pivonello, R., Faggiano, A., Lombardi, G., & Savastano, S. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0181 · Cited by 186
Surgical Treatment of Prolactin-Secreting Pituitary Adenomas: Early Results and Long-Term Outcome
Losa, M. (2002) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.7.3180 · Cited by 181
Temozolomide: a novel treatment for pituitary carcinoma
Lim, S., Shahinian, H., Maya, M. M., Yong, W., & Heaney, A. P. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70728-8 · Cited by 181
Functional role of estrogen in pituitary tumor pathogenesis
Heaney, A. P., Fernando, M., & Melmed, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14264 · Cited by 181
Self-citationPregnancy outcome after treatment with the ergot derivative, cabergoline
Robert, E., Musatti, L., Piscitelli, G., & Ferrari, C. I. (1996) · Reproductive Toxicology · doi:10.1016/0890-6238(96)00063-9 · Cited by 178
Sexual dysfunction and antipsychotic treatment
Cutler, A. J. (2003) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00113-0 · Cited by 176
Serum prolactin levels in untreated primary hypothyroldism
Honbo, K. S., Van Herle, A. J., & Kellett, K. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90517-x · Cited by 173
MEDICAL TREATMENT OF PROLACTINOMAS
Molitch, M. E. (1999) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70061-x · Cited by 171
LIM, V. S., KATHPALIA, S. C., & FROHMAN, L. A. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-48-1-101 · Cited by 165
Primary Medical Therapy of Micro- and Macroprolactinomas in Men
Pinzone, J. J. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.9.3053 · Cited by 161
The Impact on Clinical Practice of Routine Screening for Macroprolactin
Gibney, J., Smith, T. P., & McKenna, T. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2234 · Cited by 159
Effects of Psychiatric Disorders and Psychotropic Medications on Prolactin and Bone Metabolism
Misra, M., Papakostas, G. I., & Klibanski, A. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n1205 · Cited by 156 · cited 1×
“There are also reports of increased risk of bone loss in women with antipsychotic-induced hyperprolactinemia (46, 47).”
BackgroundBush, Z. M., Longtine, J. A., Cunningham, T. L., Schiff, D., Jane, J. A., Vance, M. L., Thorner, M. O., Laws, E. R., & Lopes, M. B. S. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-0441 · Cited by 153
Bigazzi, M., Ronga, R., Lancranjan, I., FERRARO, S., Branconi, F., Buzzoni, P., Martorana, G., Scarselli, G., & del Pozo, E. (1979) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-48-1-9 · Cited by 151
Colao, A. A. L., Abs, R., González-Bárcena, D., Chanson, P., Paulus, W. E., & Kleinberg, D. L. (2007) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03000.x · Cited by 148
Self-citationVisual Loss in Pregnant Women with Pituitary Adenomas
Kupersmith, M. J., Rosenberg, C., & Kleinberg, D. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-7-199410010-00001 · Cited by 142
Self-citationMcCormack, A. I., McDonald, K. L., Gill, A. J., Clark, S. J., Burt, M. G., Campbell, K. A., Braund, W. J., Little, N., Cook, R., Grossman, A. B., et al. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03487.x · Cited by 136
Prolactin: Evidence That It Is Separate from Growth Hormone in Human Blood
FRANTZ, A. G., & Kleinberg, D. L. (1970) · Science · doi:10.1126/science.170.3959.745 · Cited by 135
Self-citationKars, M., Delgado, V., Holman, E. R., Feelders, R. A., Smit, J. W. A., Romijn, J. A., Bax, J. J., & Pereira, A. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2658 · Cited by 135
Vilar, L., de Freitas, M. C., Naves, L. A., Casulari, L. A., Azevedo, M. F., Montenegro, R. M., Barros, A., Faria, M. D. S., Nascimento, G. C., Lima, J. G., et al. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346388 · Cited by 133
Vallette-Kasic, S., Serri, K., Rivera, J., Santagata, P., Delorme, S., Garfield, N., Kahtani, N., Beauregard, H., Aris-Jilwan, N., Houde, G., et al. (2008) · Pituitary · doi:10.1007/s11102-008-0134-2 · Cited by 132
Long‐term follow‐up of patients with hyperprolactinaemia
Jeffcoate, W. J., Pound, N., Sturrock, N. D. C., & Lambourne, J. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00824.x · Cited by 129
Ono, M., Miki, N., Amano, K., Kawamata, T., Seki, T., Makino, R., Takano, K., Izumi, S., Okada, Y., & Hori, T. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2605 · Cited by 129
Hagen, C., Schroeder, H. D., Hansen, S., Hagen, C., & Andersen, M. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0389 · Cited by 124
Bronstein, M. D. (2005) · Pituitary · doi:10.1007/s11102-005-5083-4 · Cited by 123
Hou, S., Grossman, S. D., & Molitch, M. E. (1985) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(85)80181-5 · Cited by 122
Biswas, M., Smith, J., Jadon, D. R., McEwan, P. C., Rees, A., Evans, M., Scanlon, M. F., & Davies, J. S. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02293.x · Cited by 122
Follow-Up of Children Born of Bromocriptine-Treated Mothers
Raymond, J. P., Goldstein, E., Konopka, P., Leleu, M. F., Merceron, R. E., & Loria, Y. (2008) · Hormone Research · doi:10.1159/000180100 · Cited by 120
Valvular heart disease and the use of cabergoline for the treatment of prolactinoma
Herring, N., Szmigielski, C. A., Becher, H. H., Karavitaki, N., & Wass, J. A. H. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03458.x · Cited by 119
Self-citationCabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti, P., Livadariu, E., Марков, М. Б., Daly, A., Burlacu, M., Betea, D., Piérard, L., & Beckers, A. M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0213 · Cited by 119
Recurrence of Hyperprolactinemia after Withdrawal of Long-Term Cabergoline Therapy
Kharlip, J., Salvatori, R., Yenokyan, G., & Wand, G. S. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2103 · Cited by 118
Prolactin‐Secreting pituitary tumors
Antunes, J. L. F., Housepian, E. M., FRANTZ, A. G., Holub, D. A., Hui, R. M., Carmel, P. W., & Quest, D. O. (1977) · Annals of Neurology · doi:10.1002/ana.410020210 · Cited by 116
Wakil, A., Rigby, A. S., Clark, A. L., Kallvikbacka‐Bennett, A., & Atkin, S. L. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0365 · Cited by 115
Kovács, K., Horváth, É., Syro, L. V., Uribe, H., Penagos, L. C., Ortiz, L. D., & Fadul, C. E. (2006) · Human Pathology · doi:10.1016/j.humpath.2006.07.014 · Cited by 110
Konopka, P., Raymond, J. P., Merceron, R. E., & Sénèze, J. (1983) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(83)90968-7 · Cited by 110
Cocaine Effects on Pulsatile Secretion of Anterior Pituitary, Gonadal, and Adrenal Hormones*
Mendelson, J. H., Mello, N. K., TEOH, S. K., Ellingboe, J., & COCHIN, J. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-6-1256 · Cited by 104
Forearm and Vertebral Bone Mineral in Treated and Untreated Hyperprolactinemic Amenorrhea*
Schlechte, J., El-Khoury, G. Y., Kathol, M. H., & Walkner, L. M. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-5-1021 · Cited by 103
Self-citationHuman Prolactin: Measurement in Plasma by In Vitro Bioassay
Kleinberg, D. L., & FRANTZ, A. G. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106643 · Cited by 103
Self-citationDopamine Resistance of Prolactinomas
Molitch, M. E. (2003) · Pituitary · doi:10.1023/a:1026225625897 · Cited by 102
Kars, M., Souverein, P. C., Herings, R. M. C., Romijn, J. A., Vandenbroucke, J. P., de Boer, A., & Dekkers, O. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0177 · Cited by 102
Barkan, A. L., & Chandler, W. F. (1998) · Neurosurgery · doi:10.1097/00006123-199804000-00126 · Cited by 101
Corenblum, B., & Donovan, L. (1993) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55819-1 · Cited by 97
Colao, A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.6.2247 · Cited by 97
Bogazzi, F., Buralli, S., Manetti, L., Raffaelli, V., Cigni, T., Lombardi, M., Boresi, F., Taddei, S., Salvetti, A., & Martino, E. (2008) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2008.01779.x · Cited by 96
Morphine inhibits cortisol and stimulates prolactin secretion in man
Zis, A. P., Haskett, R. F., Ariav Albala, A., & Carroll, B. J. (1984) · Psychoneuroendocrinology · doi:10.1016/0306-4530(84)90050-7 · Cited by 96
Clinical history and outcome of 59 patients with idiopathic hyperprolactinemia
Sluijmer, A. V., & Lappöhn, R. E. (1992) · Fertility and Sterility · doi:10.1016/s0015-0282(16)55139-5 · Cited by 92
Glezer, A., Soares, C. R. J., Vieira, J. G. H., Giannella‐Neto, D., Ribela, M. T. C. P., Goffin, V., & Bronstein, M. D. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1831 · Cited by 89
Calarge, C. A., Ellingrod, V. L., Ación, L., Miller, D. D., Moline, J., Tansey, M., & Schlechte, J. (2009) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328329a60f · Cited by 88
Self-citationJohnston, D. G., Prescott, R. W. G., Kendall‐Taylor, P., Hall, K., Crombie, A. L., Hall, R., McGregor, A. M., Watson, M. J., & Cook, D. B. (1983) · The American Journal of Medicine · doi:10.1016/0002-9343(83)90418-7 · Cited by 87
Rosa, M. D., Zarrilli, S., Vitale, G., Somma, C. D., Orio, F., Tauchmanovà, L., Lombardi, G., & Colao, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030852 · Cited by 87
Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women
Crosignani, P. G., MATTEI, A. M., Severini, V., Cavioni, V., Maggioni, P., & Testa, G. (1992) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/0028-2243(92)90094-f · Cited by 85
Macroprolactinemia: a New Cause of Hyperprolactinemia
Hattori, N. (2003) · Journal of Pharmacological Sciences · doi:10.1254/jphs.92.171 · Cited by 83
Petakov, M. S., Damjanovic, S. S., Nikolic-Djurovic, M., Dragojlović, Z., Obradović, S., Gligorović, M. S., Simic, M., & Popović, V. P. (1998) · Journal of Endocrinological Investigation · doi:10.1007/bf03347299 · Cited by 83
Pituitary Tumors Secreting Growth Hormone and Prolactin
Melmed, S. K., BRAUNSTEIN, G. D., CHANG, J. R., & BECKER, D. P. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-105-2-238 · Cited by 81
Self-citationProlactin-producing microadenomas in pregnancy.
Divers, W. A., & Yen, S. S. C. (1983) · PubMed · Cited by 79
Malignant prolactinoma: case report and review of the literature
Kars, M., Roelfsema, F., Romijn, J. A., & Pereira, A. M. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02268 · Cited by 79
De Rosa, M., Ciccarelli, A., Zarrilli, S., Guerra, E., Gaccione, M., Di Sarno, A., Lombardi, G., & Colao, A. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02461.x · Cited by 76 · cited 1×
“In men, 6 months of treatment with cabergo-line (0.5–1 mg twice weekly) restored nocturnal penile tu-mescence (76) and sperm count and motility (77, 78).”
BackgroundInfluentialTwo-year treatment with oral contraceptives in hyperprolactinemic patients
Testa, G., Vegetti, W., Motta, T., Alagna, F., Bianchedi, D., Carlucci, C., Bianchi, M., Parazzini, F., & Crosignani, P. G. (1998) · Contraception · doi:10.1016/s0010-7824(98)00069-9 · Cited by 75
Webster, J., Piscitelli, G., Polli, A., D'Alberton, A., Falsetti, L., Ferrari, C. I., FIORETTI, P., Giordano, G., L'Hermite, M., CICCARELLI, E., et al. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb01485.x · Cited by 72
Should macroprolactin be measured in all hyperprolactinaemic sera?
McKenna, T. J. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2009.03577.x · Cited by 70
Risperidone-Associated Hyperprolactinemia
Kearns, A. E., GOFF, D. C., Hayden, D. L., & Daniels, G. H. (2000) · Endocrine Practice · doi:10.4158/ep.6.6.425 · Cited by 67
Kukstas, L. A., Domec, C., Bascles, L., Bonnet, J., Verrier, D., Israël, J.-M., & Vincent, J. (1991) · Endocrinology · doi:10.1210/endo-129-2-1101 · Cited by 64
Cabergoline Treatment of Risperidone-Induced Hyperprolactinemia
Cavallaro, R., Cocchi, F., Angelone, S. M., Lattuada, E., & Smeraldi, E. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0207 · Cited by 63
Hyperprolactinaemia in 271 women: up to three decades of clinical follow‐up
Berinder, K., Stackenäs, I., Akre, O., Hirschberg, A. L., & Hulting, A. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02364.x · Cited by 63
Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide
Freda, P. U., Andreadis, C. B., Khandji, A. G., Khoury, M., Bruce, J. N., Jacobs, T. P., & Wardlaw, S. L. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.1.6329 · Cited by 60
Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia
Ataya, K. M., Mercado, A., Kartaginer, J., Abbasi, A., & Moghissi, K. S. (1988) · Fertility and Sterility · doi:10.1016/s0015-0282(16)60365-5 · Cited by 60
Prolactinoma and estrogens: pregnancy, contraception and hormonal replacement therapy
Christin‐Maître, S., Delemer, B., Touraine, P. A., & Young, J. (2007) · Annales d Endocrinologie · doi:10.1016/j.ando.2007.03.008 · Cited by 59
Tollin, S. R. (2000) · Journal of Endocrinological Investigation · doi:10.1007/bf03345068 · Cited by 59
Lu, M., Shen, W. W., & Chen, C.-H. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.09.016 · Cited by 58
Pascal-Vigneron, V., Weryha, G., Bosc, M., & Leclere, J.-C. (1995) · PubMed · Cited by 53
Suppressed Prolactin Response to Dynorphin A1–13 in Methadone-Maintained Versus Control Subjects
Bart, G. B., Borg, L., Schluger, J. H., Green, M., Ho, A., & Kreek, M. J. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.050682 · Cited by 53
Antipsychotic-Induced Hyperprolactinemia: A Cross-Sectional Survey
Johnsen, E., Kroken, R. A., Abaza, M., Olberg, H. K., & Jørgensen, H. A. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31818ba5d8 · Cited by 52
Radiotherapy for Pituitary Adenomas
Brada, M., & Jankowska, P. (2008) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.10.005 · Cited by 51
Hyperprolactinemia and contraception: a prospective study.
Luciano, A. A., Sherman, B. M., Chapler, F. K., Hauser, K. S., & Wallace, R. B. (1985) · PubMed · Cited by 50
Patients with macroprolactinaemia: clinical and radiological features
Donadio, F., Barbieri, A., Angioni, R., Mantovani, G., Beck‐Peccoz, P., Spada, A., & Lania, A. G. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01823.x · Cited by 48
Pituitary disorders during pregnancy.
Molitch, M. (2006) · Endocrinology and metabolism clinics of North America (Print) · doi:10.1016/j.ecl.2005.09.011 · Cited by 48
Serum prolactin concentration in patients taking neuroleptic drugs
Pollock, A., & McLaren, E. H. (1998) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1998.00569.x · Cited by 46
Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy
Kovács, K., Ştefăneanu, L., Horváth, É., Buchfelder, M., Fahlbusch, R., & Becker, W. (1995) · Journal of neurosurgery · doi:10.3171/jns.1995.82.5.0886 · Cited by 43
Treatment of Risperidone-Induced Hyperprolactinemia with a Dopamine Agonist in Children
Cohen, L. G., & Biederman, J. (2001) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454601317261618 · Cited by 42
Keye, W. R., Yuen, B. H., Knopf, R. F., & Jaffe, R. B. (1976) · PubMed · Cited by 38
Pattern of Development of Hyperprolactinemia After Initiation of Haloperidol Therapy
Spitzer, M., SAJJAD, R., & BENJAMIN, F. (1998) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(98)00066-0 · Cited by 35
Pituitary Gland Enlargement in Primary Hypothyroidism: A Report of 5 Cases with Follow-Up Data
Ahmed, M., Banna, M., Sakati, N., & Woodhouse, N. (2008) · Hormone Research · doi:10.1159/000181287 · Cited by 34
Neuroleptic-associated hyperprolactinemia. Can it be treated with bromocriptine?
Smith, S. L. (1992) · PubMed · Cited by 32
Popadić, A., Witzmann, A., Buchfelder, M., Eiter, H., & Komminoth, P. (1999) · Surgical Neurology · doi:10.1016/s0090-3019(97)00458-8 · Cited by 30
Dopamine Agonist Therapy in Prolactinomas: When Can Treatment Be Discontinued?
Klibanski, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0999 · Cited by 27
Valvular Heart Disease and the Use of Dopamine Agonists for Parkinson's Disease
Verma, A. (2008) · Yearbook of Neurology and Neurosurgery · doi:10.1016/s0513-5117(08)79010-0 · Cited by 27
Aripiprazole resolves amisulpride and ziprasidone‐induced hyperprolactinemia
Saitis, M., Papazisis, G., Katsigiannopoulos, K., & Kouvelas, D. (2008) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.2008.01859.x · Cited by 18
Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma
Bonert, V. S., & Melmed, S. K. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0222 · Cited by 14
Self-citationLudlam, W. H. (2010) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(10)79596-2 · Cited by 14
Pregnancy outcome after treatment with ergot derivative cabergoline
Robert, E., Musatti, L., Piscitelli, G., & Ferrari, C. (1996) · Reproductive Toxicology · doi:10.1016/0890-6238(96)80189-4 · Cited by 12
Ono, M., Miki, N., Seki, T., & Makino, R. (2010) · The Endocrine Society's 92nd Annual Meeting, June 19–22, 2010 - San Diego · doi:10.1210/endo-meetings.2010.part3.p7.p3-315 · Cited by 12
Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data
Buurman, H., & Saeger, W. (2006) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2006-932930 · Cited by 9
Ludlam, W. H. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79037-1 · Cited by 2
Cited by
Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2350 · Cited by 1,919
Diagnosis and Treatment of Pituitary Adenomas: A Review
Molitch, M. E. (2017) · JAMA · doi:10.1001/jama.2016.19699 · Cited by 933
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Self-citationEvaluation and Management of Testosterone Deficiency: AUA Guideline
Mulhall, J. P., Trost, L. W., Brannigan, R. E., Kurtz, E. G., Redmon, J. B., Chiles, K. A., Lightner, D. J., Miner, M. M., Murad, M. H., Nelson, C. J., et al. (2018) · Journal of Urology · doi:10.1016/j.juro.2018.03.115 · Cited by 766
Pituitary-Tumor Endocrinopathies
Melmed, S. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1810772 · Cited by 604
Self-citation
Metadata
- Authors
- Melmed, S., Casanueva, F. F., Hoffman, A. R., Kleinberg, D. L., Montori, V. M., Schlechte, J. A., & Wass, J. A. H.
- Affiliations
- Cedars-Sinai Medical Center (US)
- Universidade de Santiago de Compostela (ES)
- VA Palo Alto Health Care System (US)
- New York University (US)
- University of Iowa (US)
- Churchill Hospital (GB)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-02
- Volume
- 96
- Issue
- 2
- Pages
- 273-288
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2019055295
- Semantic Scholar
- 43454263bc46394124a75b19ce2b73452ff5e993
- Cited by
- 1,844
- References
- 141
- Citations by year
- 2026: 133 · 2025: 125 · 2024: 141 · 2023: 150 · 2022: 186 · 2021: 170 · 2020: 138 · 2019: 148 · 2018: 103 · 2017: 107 · 2016: 102 · 2015: 97 · 2014: 76 · 2013: 66 · 2012: 71
- FWCI
- 61.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- RUNA. Repositorio Institucional del Sergas (Servicio Gallego de Salud (SERGAS)) (submittedVersion, other-oa)
- Funders
- U.S. Department of Defense
- Eli Lilly and Company
- Pfizer
- Teva Pharmaceutical Industries
- European Society of Endocrinology
- Novo Nordisk
- Ipsen
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- hyperprolactinemia, prolactinoma, drug-induced hyperprolactinemia, prolactinoma treatment, pregnancy
- MeSH terms
- Adult, Female, Humans, Hyperprolactinemia, Pituitary Neoplasms, Pregnancy, Prolactinoma, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.